Acne vulgaris, a multifactorial skin disease, affects both the patient’s physical and emotional well-being. While standard over-the-counter options have been readily available, new solutions are needed that would address complexion issues, such as rough texture, uneven tone, and postacne marks. As abnormal desquamation is an important factor in both acne formation and uneven complexion, topical ingredients that enhance cell turnover rate, such as alpha-hydroxy acids (AHAs) and polyhydroxy acids (PHAs), can play an important role in improving acne patients’ skin; however, AHAs can be irritating, especially at higher levels. A novel 10% multiacid serum combining exfoliating 5% glycolic acid; 2.5% mandelic acid; a lipophilic AHA ideal for acne-prone skin; 2.5% gluconolactone, a gentle PHA with humectancy and skin clarifying properties; and 0.5% salicylic acid was developed and evaluated for its unique ability to balance improvements in mild-to-moderate acne patients with tolerability for daily use. Acne improvement, skin complexion benefits, and tolerability of this novel daily-use multi-acid serum were assessed in a 12-week clinical study in 31 male and female subjects across diverse skin tones. A statistically significant reduction (P < .05) in total acne lesions was seen as early as 2 weeks, and global severity improvement by 4 weeks. Significant improvements in uneven tone, texture, post-acne marks, and skin blotchiness by investigator assessment was shown, and an acne-related Quality of Life Assessment (aQOL) demonstrated improvement in subject emotional well-being. There were no reported adverse events, and this multi-acid serum was considered well-tolerated for daily use.
Read full abstract